SG11201907956UA - Biodegradable drug-polymer conjugate - Google Patents

Biodegradable drug-polymer conjugate

Info

Publication number
SG11201907956UA
SG11201907956UA SG11201907956UA SG11201907956UA SG11201907956UA SG 11201907956U A SG11201907956U A SG 11201907956UA SG 11201907956U A SG11201907956U A SG 11201907956UA SG 11201907956U A SG11201907956U A SG 11201907956UA SG 11201907956U A SG11201907956U A SG 11201907956UA
Authority
SG
Singapore
Prior art keywords
victoria
international
group
functional group
street
Prior art date
Application number
SG11201907956UA
Other languages
English (en)
Inventor
Stephen Birkett
Andrew Donohue
Asha D'souza
Sarah Man Yee Ng
Adrian Sulistio
Russell Tait
David Valade
Alan Naylor
Jason Watling
Carmen Scullino
Original Assignee
Polyactiva Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/458,546 external-priority patent/US10113033B2/en
Priority claimed from AU2017900888A external-priority patent/AU2017900888A0/en
Application filed by Polyactiva Pty Ltd filed Critical Polyactiva Pty Ltd
Publication of SG11201907956UA publication Critical patent/SG11201907956UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593Polyesters, e.g. PLGA or polylactide-co-glycolide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595Polyamides, e.g. nylon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts or implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/08Polyhydrazides; Polytriazoles; Polyaminotriazoles; Polyoxadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201907956UA 2017-03-14 2018-03-14 Biodegradable drug-polymer conjugate SG11201907956UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/458,546 US10113033B2 (en) 2013-03-08 2017-03-14 Polymer conjugate for delivery of a bioactive agent
AU2017900888A AU2017900888A0 (en) 2017-03-14 Biodegradable drug-polymer conjugate
PCT/AU2018/050234 WO2018165711A1 (en) 2017-03-14 2018-03-14 Biodegradable drug-polymer conjugate

Publications (1)

Publication Number Publication Date
SG11201907956UA true SG11201907956UA (en) 2019-09-27

Family

ID=63521659

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201907956UA SG11201907956UA (en) 2017-03-14 2018-03-14 Biodegradable drug-polymer conjugate
SG11201907931WA SG11201907931WA (en) 2017-03-14 2018-03-14 Drug-polymer conjugate

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201907931WA SG11201907931WA (en) 2017-03-14 2018-03-14 Drug-polymer conjugate

Country Status (14)

Country Link
US (2) US11787906B2 (https=)
EP (2) EP3595670A4 (https=)
JP (2) JP7355649B2 (https=)
KR (2) KR102642432B1 (https=)
CN (4) CN110461336A (https=)
AU (2) AU2018233158B2 (https=)
CA (1) CA3054084A1 (https=)
CL (1) CL2019002600A1 (https=)
IL (2) IL269321B (https=)
MX (2) MX2019010837A (https=)
NZ (2) NZ756626A (https=)
SG (2) SG11201907956UA (https=)
WO (2) WO2018165710A1 (https=)
ZA (2) ZA201905589B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11696955B2 (en) 2017-03-14 2023-07-11 Polyactiva Pty Ltd Drug-polymer conjugate
MX2019010837A (es) * 2017-03-14 2019-12-19 Polyactiva Pty Ltd Conjugado biodegradable de farmaco-polimero.
WO2021024041A1 (en) 2019-08-07 2021-02-11 Ripple Therapeutics Corporation Controlled release drug dimers
CA3154867A1 (en) * 2019-09-19 2021-03-25 Polyactiva Pty Ltd Biodegradable drug-polymer conjugate
MX2022013665A (es) 2020-05-01 2022-11-30 Ripple Therapeutics Corp Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares.
WO2024084056A1 (en) * 2022-10-21 2024-04-25 Etherna Immunotherapies Nv Ionizable lipids

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1044797B (it) 1974-10-15 1980-04-21 Ferruti Paolo Alti polimeri contenenti radicali prostaglandinici processo per la loro preparazione e loro impiego
JPH03220201A (ja) 1988-11-18 1991-09-27 Eisai Co Ltd プロスタグランジン類と多糖類の結合体
JP4419368B2 (ja) 2002-07-25 2010-02-24 小野薬品工業株式会社 プロスタグランジン誘導体およびその誘導体を有効成分として含有する薬剤
CA2617907A1 (en) 2005-08-05 2007-02-15 Syntarga B.V. Triazole-containing releasable linkers and conjugates comprising the same
MY155629A (en) 2008-10-10 2015-11-13 Polyactiva Pty Ltd Biodegradable polymer-bioactive moiety conjugates
SI2340271T1 (sl) 2008-10-10 2019-08-30 Polyactiva Pty Ltd. Konjugati polimer-bioaktivnega sredstva
US8535655B2 (en) * 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US20120130045A1 (en) 2009-06-01 2012-05-24 Ablitech, Inc. Biomolecule-polymer conjugates and methods of making same
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
WO2012075117A2 (en) 2010-12-01 2012-06-07 Ablitech, Inc. Small molecule-polymer conjugates and methods of making same
WO2012139164A1 (en) * 2011-04-12 2012-10-18 Polyactiva Pty Ltd Polymer conjugated prostaglandin analogues
JP2013035802A (ja) 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
MY190370A (en) * 2012-06-26 2022-04-18 Polyactiva Pty Ltd Polymer-nsaid conjugate
US10113033B2 (en) 2013-03-08 2018-10-30 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent
DK2964224T3 (en) * 2013-03-08 2024-10-14 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent
MX2019010837A (es) * 2017-03-14 2019-12-19 Polyactiva Pty Ltd Conjugado biodegradable de farmaco-polimero.
US11696955B2 (en) 2017-03-14 2023-07-11 Polyactiva Pty Ltd Drug-polymer conjugate
US11207417B2 (en) 2017-03-14 2021-12-28 Polyactiva Pty Ltd Drug-polymer conjugate

Also Published As

Publication number Publication date
EP3595728A1 (en) 2020-01-22
WO2018165711A1 (en) 2018-09-20
JP2020510690A (ja) 2020-04-09
JP2020510692A (ja) 2020-04-09
WO2018165710A1 (en) 2018-09-20
JP7204661B2 (ja) 2023-01-16
IL269323A (en) 2019-11-28
CA3054084A1 (en) 2018-09-20
BR112019018914A2 (pt) 2020-06-30
IL269321B (en) 2022-07-01
KR102642432B1 (ko) 2024-02-28
CN120919337A (zh) 2025-11-11
AU2018233158A1 (en) 2019-09-12
KR20190124243A (ko) 2019-11-04
CN110662561A (zh) 2020-01-07
ZA201906133B (en) 2021-04-28
CN110461336A (zh) 2019-11-15
US11787906B2 (en) 2023-10-17
CA3054328A1 (en) 2018-09-20
US20240247106A1 (en) 2024-07-25
AU2018233159B8 (en) 2024-08-01
AU2018233159A1 (en) 2019-09-12
AU2018233159B2 (en) 2024-05-02
US12503553B2 (en) 2025-12-23
CL2019002600A1 (es) 2020-04-03
EP3595670A4 (en) 2021-05-12
KR20190123776A (ko) 2019-11-01
CN120919336A (zh) 2025-11-11
IL269323B (en) 2022-07-01
IL269321A (en) 2019-11-28
MX2019010904A (es) 2019-12-09
SG11201907931WA (en) 2019-09-27
JP7355649B2 (ja) 2023-10-03
KR102642433B1 (ko) 2024-02-28
AU2018233158B2 (en) 2024-04-11
NZ756626A (en) 2022-10-28
ZA201905589B (en) 2020-07-29
EP3595670A1 (en) 2020-01-22
NZ757356A (en) 2022-10-28
AU2018233159C1 (en) 2025-01-02
AU2018233159A8 (en) 2024-08-01
US20200123322A1 (en) 2020-04-23
MX2019010837A (es) 2019-12-19
EP3595728A4 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
SG11201907956UA (en) Biodegradable drug-polymer conjugate
SG11201900501RA (en) Cannabis composition
SG11201909433XA (en) Targeted compositions
SG11201811783YA (en) Functionalised chromatography medium comprising polymer nanofibres and process of preparation thereof
SG11201907742YA (en) Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof
SG11201910115XA (en) Rnai approach for crop pest protection
SG11201809064QA (en) Chimeric neurotoxins
SG11201408064PA (en) Macrocyclic inhibitors of flaviviridae viruses
SG11201906748PA (en) Microbial cells, methods of producing the same, and uses thereof
SG11201907034PA (en) Methods of treating influenza
SG11201909997VA (en) Biodegradable bone glue
SG11201900699QA (en) Drug conjugates with self-stabilizing linkers having improved physiochemical properties
SG11201809801RA (en) Methods for synthesizing acryloyl-based copolymers, terpolymers
SG11201810521WA (en) Apparatus and method to form entry bleb for subretinal delivery of therapeutic agent
SG11201906804UA (en) Zwitterionically modified polymers and hydrogels
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201810396QA (en) Pegylated carfilzomib compounds
SG11201906222WA (en) Jak1 selective inhibitors
SG11201408045UA (en) MACROCYCLIC INHIBITORS OF <i>FLAVIVIRIDAE</i> VIRUSES
SG11201408054RA (en) Pegylated oxm variants
SG11201408605UA (en) Methods for biodegradable derivatization of cellulosic surfaces
SG11201906441YA (en) A modified alginate copolymer, alginate nanoparticle and applications thereof
SG11201810454YA (en) Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
SG11201804454XA (en) A polymeric composition
SG11201809681WA (en) Low-to-mid range water-reducing polymer with mixed polyoxyalkylene side chains